According to Zacks, “NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company’s product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. “
A number of other research analysts have also weighed in on NXTC. Piper Jaffray Companies reissued a “positive” rating and issued a $95.00 target price (up from $54.00) on shares of NextCure in a research note on Monday. Morgan Stanley raised their target price on shares of NextCure from $25.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Finally, Bank of America raised their target price on shares of NextCure from $27.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, September 9th.
NextCure (NASDAQ:NXTC) last released its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. On average, equities analysts anticipate that NextCure will post -1.8 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $40,611,000. Sofinnova Investments Inc. acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $37,777,000. Citadel Advisors LLC acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $16,385,000. Cormorant Asset Management LP acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $14,980,000. Finally, Hillhouse Capital Management LTD. acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $14,659,000. Institutional investors and hedge funds own 47.19% of the company’s stock.
NextCure Company Profile
There is no company description available for NextCure Inc
Further Reading: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.